Pembrolizumab Yields Lasting Merkel-Cell Carcinoma Responses
April 20, 2016
Abstract
In a phase II single-arm study, the PD-1 checkpoint inhibitor pembrolizumab effectively shrank tumors and prolonged survival in more than half of patients with Merkel cell carcinoma. Responses were significantly more durable that those typically seen with chemotherapy.
View the clinical publication